Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 13/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5428237 | 1.00 | TNKS (0.46) | TNKSTNKS2HDAC6HDAC1HDAC8 | |
| SCHEMBL5430336 | 0.85 | QPCT (0.51) | TNKSTNKS2HDAC6HDAC1HDAC8 | |
| SCHEMBL5431723 | 0.85 | QPCT (0.51) | TNKSTNKS2HDAC6HDAC1HDAC8 | |
| SCHEMBL5430340 | 0.85 | QPCT (0.51) | TNKSTNKS2HDAC6HDAC1HDAC8 | |
| SCHEMBL14502326 | 0.81 | IDH1 (0.51) | TNKSTNKS2HDAC6HDAC1HDAC8 | |
| SCHEMBL5429899 | 0.81 | IDH1 (0.51) | TNKSTNKS2HDAC6HDAC1HDAC8 | |
| SCHEMBL19745746 | 0.81 | HDAC6 (0.53) | HDAC6HDAC1HDAC8HTR7 | |
| SCHEMBL19745745 | 0.81 | HDAC6 (0.53) | HDAC6HDAC1HDAC8HTR7 | |
| SCHEMBL14556222 | 0.79 | TNKS (0.57) | TNKSTNKS2HDAC6HDAC1HDAC8 | |
| SCHEMBL14556224 | 0.79 | TNKS (0.57) | TNKSTNKS2HDAC6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223870-B2 | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction | PFIZER INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | PFIZER INC | 2007-03-01 | — | — | US | disclosed |
| EP-1562916-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004039788-A1 | METHODS FOR PREPARING N-ARYLATED OXAZOLIDINONES VIA A COPPER CATALYZED CROSS COUPLING REACTION | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049759-A1 | Methods for Preparing N-Arylated Oxazolidinones Via A Copper Catalyzed Cross Coupling | AOC2, SOD1, AOC3 | TNKS 1391/4885TNKS2 1486/4885HDAC6 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.